Cargando…

Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity

Detalles Bibliográficos
Autores principales:	Walton, Josephine B., Farquharson, Malcolm, Mason, Susan, Port, Jennifer, Kruspig, Bjorn, Dowson, Suzanne, Stevenson, David, Murphy, Daniel, Matzuk, Martin, Kim, Jaeyeon, Coffelt, Seth, Blyth, Karen, McNeish, Iain A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897571/ https://www.ncbi.nlm.nih.gov/pubmed/29651149 http://dx.doi.org/10.1038/s41598-018-24099-3

Ejemplares similares

CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
por: Walton, Josephine B., et al.
Publicado: (2017)

RIPK3 promotes adenovirus type 5 activity
por: Weigert, Melanie, et al.
Publicado: (2017)

Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management
por: Rumford, Megan, et al.
Publicado: (2020)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer
por: Leung, Elaine Y.L., et al.
Publicado: (2020)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
por: Moreno, Victor, et al.
Publicado: (2021)

Analysis of PTEN in two BRCA1 and BRCA2 wild-type familial breast cancer patients
por: Akouchekian, Mansoureh, et al.
Publicado: (2015)

Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells
por: Leung, Elaine Y. L., et al.
Publicado: (2021)

The Emerging Role of Interleukin 1β (IL-1β) in Cancer Cachexia
por: Laird, Barry J., et al.
Publicado: (2021)

Ultrahigh Resolution Lipid Mass Spectrometry Imaging of High-Grade Serous Ovarian Cancer Mouse Models
por: Ma, Xin, et al.
Publicado: (2023)

Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair
por: Minami, Akari, et al.
Publicado: (2014)

PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency
por: Noll, Aurélia, et al.
Publicado: (2016)

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
por: Conroy, Michael, et al.
Publicado: (2017)

Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
por: Bruand, Marine, et al.
Publicado: (2021)

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
por: Hollis, Robert L., et al.
Publicado: (2019)

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report
por: Buttitta, Fiamma, et al.
Publicado: (2023)

Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
por: Spiliopoulou, Pavlina, et al.
Publicado: (2022)

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
por: Imyanitov, Evgeny N
Publicado: (2009)

The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents
por: Kim, Geon, et al.
Publicado: (2019)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Potent immunogenicity in BRCA1‐mutated patients with high‐grade serous ovarian carcinoma
por: Dai, Ying, et al.
Publicado: (2018)

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2
por: Clarfield, Lauren, et al.
Publicado: (2022)

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality
por: Bray, Chandler, et al.
Publicado: (2023)

Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses
por: Blagih, Julianna, et al.
Publicado: (2020)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
por: Cheng, Zhao, et al.
Publicado: (2022)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis
por: Salwa, Amreen, et al.
Publicado: (2021)

Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
por: Mylavarapu, Sanghamitra, et al.
Publicado: (2018)

Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
por: Tookman, Laura, et al.
Publicado: (2020)

PTEN deficiency exposes a requirement for an ARF GTPase module for integrin‐dependent invasion in ovarian cancer
por: Nikolatou, Konstantina, et al.
Publicado: (2023)

BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
por: Li, Andrew G., et al.
Publicado: (2018)

Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer
por: Kiely, B. E., et al.
Publicado: (2011)

Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
por: Turner, Nicholas C, et al.
Publicado: (2012)

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
por: Stefansson, Olafur A., et al.
Publicado: (2012)

Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
por: Imyanitov, Evgeny, et al.
Publicado: (2021)

Mechanisms of diarrhoea
por: Booth, I.W., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_61dvq99lhtlbg49pmpssskm28a